Background. To determine the efficacy of immunoglobulin free light chain (FLC) removal by high cut-off haemodialysis (HCO-HD) as an adjuvant treatment to chemotherapy for patients with acute kidney injury complicating multiple myeloma (MM). Methods. Sixty-seven patients with dialysis-dependent renal failure secondary to MM were treated with HCO-HD and chemotherapy. Results. The population was predominately male (62.7%) with new presentation MM (75%) and did not have a history of chronic kidney disease (84%). The mean serum creatinine at presentation was 662 (SD = 349) μmol/L and of the 56.7% of patients who had a renal biopsy, 86.7% had cast nephropathy as the principal diagnosis. Eighty-five percent of patients were treated with a chemotherapy regime consisting of dexamethasone in combination with a novel agent (bortezomib or thalidomide). The median number of HCO-HD sessions was 11 (range 3-45), 97% received an extended dialysis regime. Seventy-six percent of the population had a sustained reduction in serum FLC concentrations by Day 12, of these 71% subsequently became independent of dialysis. In total, 63% of population became independent of dialysis. Factors which predicted independence of dialysis were the degree of FLC reduction at Days 12 (P = 0.002) and 21 (P = 0.005) and the time to initiating HCO-HD (P = 0.006). Conclusion. The combination of extended HCO-HD and chemotherapy resulted in sustained reductions in serum FLC concentrations in the majority of patients and a high rate of independence of dialysis.
Introduction
Dialysis-dependent acute kidney injury (AKI) occurs in up to 10% of patients with multiple myeloma (MM). The principal renal pathology in this context is the tubulointerstitial lesion cast nephropathy (myeloma kidney) a direct consequence of the high serum levels of immunoglobulin free light chains (FLCs) [1] . The clinical outcomes for this population are poor, with up to 80% of patients remaining dialysis dependent [2] . The median survival in those who do not regain independent renal function is ∼6 months [2] .
In this context, monoclonal FLCs are profoundly nephrotoxic and recent work has demonstrated that unless their serum levels are rapidly decreased, AKI will become irreversible [3, 4] . Single-centre studies have indicated that combining effective chemotherapy with extracorporeal FLC removal by high cut-off haemodialysis (HCO-HD), using a 1.1-m 2 membrane, is associated with an early reduction in serum FLC levels and subsequently a high rate of recovery of independent kidney function [5] [6] [7] . This strategy is now being further assessed in two randomized controlled trials to determine the benefit of FLC removal in addition to effective chemotherapy [EuLITE [8] and MYRE (NCT01208818)].
To date, however, the precise association between changes in serum FLC levels after the start of treatment and recovery from AKI has not been studied in a multicentre setting. Clarifying this relationship would allow the development of a tailored therapy based on an early disease response. To address this, we have analysed data reported to an international database by centres which have (i) treated patients with chemotherapy and HCO-HD for MM and dialysis-dependent AKI and (ii) measured early changes in serum FLC levels. This provides an accurate assessment of the relationship between FLC responses and renal recovery in this setting.
Materials and methods
The study was reviewed and approved by the Research and Development Department, University Hospital Birmingham, Birmingham, UK. It was designed to report the outcomes of patients treated at 16 centres in nine countries. The centres were identified based on their known use of HCO-HD for the treatment of AKI in MM. Lead clinicians were invited to enter a dataset on all patients treated at that centre with AKI, MM and HCO-HD.
Data collection
A web-based electronic case report form was used for data collection. The system was designed and maintained by Cornerstone Research Group (Burlington, Ontario, Canada). Data collection included basic demographic details, the patients' haematological and renal presentations, treatments received and clinical outcomes. Renal recovery was defined as independence of dialysis based on the clinic parameters of urine output and biochemical kidney function as assessed by the supervising nephrologist. No patient-identifiable data were collected.
Statistical methods
Descriptive data of patient characteristics, treatment details and outcomes were presented as means with SDs or frequency of occurrence with proportions for normally distributed and non-parametric data, respectively. Predictor variables that were not normally distributed were categorized into clinically meaningful categories. Clinical outcomes and the details of the HCO treatments were compared between small and large centres using chi-square or Fisher's exact test. Factors which predicted renal recovery (defined as dialysis independence) were assessed using logistic regression models. All data analyses were undertaken using SPSS version 17.0.
Results

Patient characteristics and treatment patterns
In total, investigators from 16 centres across nine countries (Australia, Austria, Denmark, Finland, Germany, Spain, Sweden, Switzerland and the UK) entered data on 67 patients treated between 10 November 2008 and 24 September 2009. Thirteen centres entered data on 1-3 patients, three centres entered data on >10 patients each, University Hospital Birmingham entered data on 22 patients, University Hospital Tübingen on 16 patients and Charité University Hospital Berlin on 10 patients.
The population was predominately male (62.7%) and had a mean age of 65.1 years (SD = 10.01). Fifty patients (74.6%) had a new presentation of MM; 17 (25.4%) had relapsing or refractory disease. Forty-six percent had a monoclonal kappa (κ) FLC and 54% a monoclonal lambda (λ) FLC. The most frequent myeloma type (55.3%) was an intact IgG, with an associated κ or λ FLC. Thirty percent had a light chain only myeloma (λ 13.4% and κ 16.4%). Sixty percent of the patients had immunoparesis at presentation. Eleven patients (16%) were known to have pre-existing chronic kidney disease (CKD defined as an estimated glomerular filtration rate of <60 mLs/min/1.73m 2 >3 months prior to presentation with AKI). The majority of patients had a renal biopsy (56.7%), of these myeloma kidney was the predominant diagnosis (86.7%). Full details of the patient population are provided in Table 1 .
The majority of the population received a chemotherapy regime including a 'novel' chemotherapeutic agent, with 58% receiving bortezomib ( Table 2 ). The median delay in initiation of chemotherapy from presentation with renal failure was 7.6 days (range 1-60). Patients received a median of 12 HCO-HD sessions (range 3-45); the 42 patients (63%) who subsequently became dialysis independent had a median of 11.5 sessions (3-45). Those who did not become dialysis independent underwent a median of 14.1 HCO sessions (3-34). The median delay in initiating HCO-HD from presentation with renal failure was 5 days (range 1-360 days); patients who subsequently became dialysis independent had a median initial delay of 3.5 versus 7 days in those patients who did not become dialysis independent (P = 0.005). Ninety-seven percent of the population received an extended dialysis schedule (>4 h) per session, predominately on one HCO dialyser (Table 3) . Dialysis-related side effects were reported in 6% of the patients (Table 3) .
Sustained reductions in serum FLCs
Forty-two patients (61%) had a reduction in serum FLC concentrations by Day 12 and 63% by Day 21. Of these patients with this early FLC reduction, 71 and 69% subsequently became independent of dialysis, respectively. Of these patients with an early reduction in serum FLC concentrations, 68% had a decline of >50% by Day 12 and 83% had a decline of >50% by Day 21.
Predictors of dialysis independence
A sustained reduction in serum FLC concentrations by Days 12 and 21 significantly increased the probability of becoming dialysis independent; odds ratio (OR) = 29 (P = 0.002) and OR = 22.3 (P = 0.005), respectively ( Table 4 ). The probability of achieving dialysis independence increased linearly with increasing levels of reduction in FLC concentrations by Day 12 (Table 4, Figure 1 ). Compared to patients who achieved no reduction in serum FLC by Day 12, a reduction of up to 25% had an OR of 8 for dialysis independence; a 25-75% reduction an OR of 28 and a 75%+ reduction an OR of a 52.
Patients in the high enrolment centres were more likely to become dialysis independent. Centres which reported more than three patients recorded dialysis independence in 70.8% of patients, in comparison to the smaller centres (with three or less patients), which had a rate of 42.1% (P = 0.03). As shown in Table 3 , analysis of treatment practices revealed that larger centres had a shorter delay between the presentation with renal failure and the initiation of HCO-HD. When differences in time between the presentation and initiation of HCO therapy were included in the analysis, there was no significant relationship between centre size and independence of dialysis.
Using an unadjusted logistic regression model, the delay in initiating HCO-HD and the degree of FLC reduction at Days 12 and 21 significantly predicted dialysis independence (Table 4) . Bortezomib chemotherapy, number of dialysis sessions, duration of dialysis, number of dialysers, time from renal failure to chemotherapy, time from chemotherapy to HCO initiation, new or relapsing MM were not statistically significant predictors.
One patient with AL-amyloid was treated with HCO-HD and achieved dialysis independence with a reduction of serum FLCs of 50 and 75% on Days 12 and 21, respectively.
Discussion
Irreversible renal failure requiring dialysis treatment greatly increases the morbidity and mortality of patients with MM [2, 9] . FLC removal by HCO-HD has recently been described as an adjuvant to effective chemotherapy for these patients. The purpose of this study was to assess the relationship between serum FLC removal and independence of dialysis in patients treated with chemotherapy and HCO-HD. Statistically significant data between large and small centres: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Data were reported for 67 patients from 16 centres in nine countries. Over 50% of patients had a renal biopsy and in these, the principal pathology was cast nephropathy. The time from presentation with renal failure to starting both chemotherapy and HCO-HD was short (7.5 and 5 days, respectively) for the majority of patients. Overall, 63% of patients became independent of dialysis. In a linear regression model, the determinants of dialysis independence were serum FLC reduction at Days 12 and 21 and the time to initiating HCO-HD. There was a linear relationship between the degree of FLC reduction achieved and the probability of dialysis independence. The OR for dialysis independence was 29 if a sustained reduction in serum FLCs occurred by Day 12. Univariant analysis showed that the number of patients treated at the reporting centre predicted outcome. However, small centres (defined as those which treated three patients or less) had longer delays to initiating HCO-HD. When this was accounted for, the difference in rates of renal recovery between large and small centres (71 and 42%, respectively) was no longer significant. Patients who had HCO-HD initiated within 7 days of presentation had a significantly greater chance of dialysis independence than those who did not.
Treatment recommendations for FLC removal by HCO-HD include the concept that an extended treatment regime (>4 h per dialysis session) would enable increased removal of FLCs by allowing time for the redistribution of FLCs from the extravascular compartment [10] . This study found that the majority of patients receiving HCO-HD were treated with an extended treatment regime. Ninety-seven percent of patients received >4 h and 48% >6 h duration. The number of patients treated with shorter schedules was too small to allow a comparison of the importance of the extended dialysis sessions. Groups (25-50 and 50-75%) were shown to have similar ORs. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
The High Cut-Off (HCO) 1100 dialyser has a small surface are of just 1.1 m 2 . There are increased clearance rates of FLCs when two dialysers are used in series [10] . The clinical relevance of these increased FLC clearance rates remains to be determined. In this study, the majority of the patients (72%) received FLC removal using one dialyser; the use of two dialysers was associated with an increased rate of dialysis independence (74 versus 58%) but this difference did not reach statistical significance.
The loss of significant quantities of albumin is a recognized consequence of treatment with HCO-HD and occurs because of the dialyser's high-molecular weight cut-off. Replacement schedules have been described [10] and replacement with human albumin solution has been recommended. In this study, 84% of the patients treated had albumin replacement.
Results from a mathematical model of FLC kinetics [5] and a clinical study [7] have demonstrated the importance of effective chemotherapy to enable sustained reductions in serum FLC concentrations to occur in patients with MM and severe renal failure. Removal of FLCs by HCO-HD without chemotherapy will have limited benefit because of the high production rates of monoclonal FLCs seen in patients with untreated MM. Potentially, the use of 'novel' chemotherapy agents such as thalidomide and, in particular, bortezomib, can result in more rapid reduction in FLC production rates than other regimes and subsequently higher rates of renal recovery [11, 12] . To date, bortezomib-based chemotherapy regimes have been shown to increase renal recovery rates for patients with moderate renal impairment [13, 14] . But in these studies, by Dimopoulus et al. and Ludwig et al., patients who required dialysis support predominately remained dialysis dependent, two of nine and three of nine patients, respectively [13, 14] . The worse outcomes for those patients with the most severe kidney failure may relate to the impaired renal clearance of FLCs in these patients [15] . Potentially, the high rate of dialysis independence seen in this study (63%) suggests that the combination of effective chemotherapy (predominately bortezomib and/or thalidomide) and FLC removal is more effective than chemotherapy alone for those patients with severe kidney impairment. While this study was not designed to address the potential benefit of one of these agents over the other, from the literature, we can conclude that both agents are safe to use in severe renal impairment and in uncontrolled studies, there is a suggestion of benefit for the proteasome inhibitor [16] .
The potential biases of a study of this type should be recognized. Firstly, there is the potential for a reporting bias, although clinicians were approached in an unselected manner, a bias between the centres which reported outcomes and those who did not could have occurred. Secondly, the study investigators were not able to monitor the data entry of the reporting clinicians.
In conclusion, the combination of FLC removal by HCO-HD and chemotherapy resulted in early reductions in serum FLC concentrations and a high rate of renal recovery in patients with severe AKI complicating MM. The decrease in serum FLC levels and time to initiating HCO-HD were the only factors which independently predicted dialysis independence in this study. 
